Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International Phase II Study of High-Dose 131-I mIBG Plus Topotecan in High-Risk Neuroblastoma
2005-002089-13Phase 2Completed
- Sponsor
- University Hospitals of Leicester NHS Trust
- Start
- Apr 2006
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Iobenguane I-131 and topotecan in neuroblastoma, sponsored by University Hospitals of Leicester NHS Trust. Primary endpoint: Primary resistant high-risk neuroblastoma response. Started Apr 2006; status: completed.
02
Drugs
Iobenguane I-131topotecan
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2005-002089-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002089-13.